Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic factors influencing outcomes in hepatocellular carcinoma patients undergoing selective internal radiation therapy.
Franzè MS, Vigneron P, Sessa A, Saitta C, Chalaye J, Tacher V, Luciani A, Regnault H, Bejan A, Rhaiem R, Sommacale D, Leroy V, Brustia R, Raimondo G, Amaddeo G. Franzè MS, et al. Among authors: regnault h. Ann Hepatol. 2024 Aug 22;30(1):101539. doi: 10.1016/j.aohep.2024.101539. Online ahead of print. Ann Hepatol. 2024. PMID: 39179159 Free article. Review.
Selective internal radiation therapy for unresectable HCC: The SIRT downstaging study.
Regnault H, Chalaye J, Galetto-Pregliasco A, Perrin C, Derbel H, Amaddeo G, Mulé S, Lequoy M, Kobeiter H, Reizine E, Itti E, Duvoux C, Laurent A, Leroy V, Sommacale D, Rasolonirina D, Luciani A, Calderaro J, Tacher V, Brustia R. Regnault H, et al. Hepatol Commun. 2024 Jun 27;8(7):e0475. doi: 10.1097/HC9.0000000000000475. eCollection 2024 Jul 1. Hepatol Commun. 2024. PMID: 38934702 Free PMC article.
Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.
Merle P, Blanc JF, Phelip JM, Pelletier G, Bronowicki JP, Touchefeu Y, Pageaux G, Gerolami R, Habersetzer F, Nguyen-Khac E, Casadei-Gardini A, Borbath I, Tran A, Wege H, Saad AS, Colombo M, Abergel A, Richou C, Waked I, Yee NS, Molé A, Attali P, Le Boulicaut J, Vasseur B; RELIVE Investigators. Merle P, et al. Lancet Gastroenterol Hepatol. 2019 Jun;4(6):454-465. doi: 10.1016/S2468-1253(19)30040-8. Epub 2019 Apr 4. Lancet Gastroenterol Hepatol. 2019. PMID: 30954567 Free article. Clinical Trial.
A French national survey on the use of antibiotic prophylaxis in cirrhotic patients.
Thevenot T, Degand T, Grelat N, Elkrief L, Christol C, Moreau R, Henrion J, Cadranel JF, Sheppard F, Bureau C, di Martino V, Pauwels A; National Association of General Hospital Hepatogastroenterologists. Thevenot T, et al. Liver Int. 2013 Mar;33(3):389-97. doi: 10.1111/liv.12093. Epub 2013 Jan 10. Liver Int. 2013. PMID: 23302021
MASLD-related HCC: Multicenter study comparing patients with and without cirrhosis.
Vitellius C, Desjonqueres E, Lequoy M, Amaddeo G, Fouchard I, N'Kontchou G, Canivet CM, Ziol M, Regnault H, Lannes A, Oberti F, Boursier J, Ganne-Carrie N. Vitellius C, et al. Among authors: regnault h. JHEP Rep. 2024 Jun 29;6(10):101160. doi: 10.1016/j.jhepr.2024.101160. eCollection 2024 Oct. JHEP Rep. 2024. PMID: 39411648 Free PMC article.
Enhancing sexual health and empowerment among migrant women sex workers: a community health worker-led intervention in Marseille, France.
Mosnier E, Hoyer M, Artigas F, Regnault H, Richard E, Michels D, Mosnier M, Inegbeze G, Robledo MS, Spire B, Vandentorren S, Lescaudron M, Eldin C, Roux P. Mosnier E, et al. Among authors: regnault h. Front Public Health. 2024 Mar 27;12:1359363. doi: 10.3389/fpubh.2024.1359363. eCollection 2024. Front Public Health. 2024. PMID: 38601503 Free PMC article.
Long-Term Overall Survival After Selective Internal Radiation Therapy for Locally Advanced Hepatocellular Carcinomas: Updated Analysis of DOSISPHERE-01 Trial.
Garin E, Tselikas L, Guiu B, Chalaye J, Rolland Y, de Baere T, Assenat E, Tacher V, Palard X, Déandreis D, Mariano-Goulart D, Amaddeo G, Boudjema K, Hollebecque A, Meerun MA, Regnault H, Vibert E, Campillo-Gimenez B, Edeline J. Garin E, et al. Among authors: regnault h. J Nucl Med. 2024 Feb 1;65(2):264-269. doi: 10.2967/jnumed.123.266211. J Nucl Med. 2024. PMID: 38212068 Free PMC article. Clinical Trial.
Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma.
Calderaro J, Ghaffari Laleh N, Zeng Q, Maille P, Favre L, Pujals A, Klein C, Bazille C, Heij LR, Uguen A, Luedde T, Di Tommaso L, Beaufrère A, Chatain A, Gastineau D, Nguyen CT, Nguyen-Canh H, Thi KN, Gnemmi V, Graham RP, Charlotte F, Wendum D, Vij M, Allende DS, Aucejo F, Diaz A, Rivière B, Herrero A, Evert K, Calvisi DF, Augustin J, Leow WQ, Leung HHW, Boleslawski E, Rela M, François A, Cha AW, Forner A, Reig M, Allaire M, Scatton O, Chatelain D, Boulagnon-Rombi C, Sturm N, Menahem B, Frouin E, Tougeron D, Tournigand C, Kempf E, Kim H, Ningarhari M, Michalak-Provost S, Gopal P, Brustia R, Vibert E, Schulze K, Rüther DF, Weidemann SA, Rhaiem R, Pawlotsky JM, Zhang X, Luciani A, Mulé S, Laurent A, Amaddeo G, Regnault H, De Martin E, Sempoux C, Navale P, Westerhoff M, Lo RC, Bednarsch J, Gouw A, Guettier C, Lequoy M, Harada K, Sripongpun P, Wetwittayaklang P, Loménie N, Tantipisit J, Kaewdech A, Shen J, Paradis V, Caruso S, Kather JN. Calderaro J, et al. Among authors: regnault h. Nat Commun. 2023 Dec 14;14(1):8290. doi: 10.1038/s41467-023-43749-3. Nat Commun. 2023. PMID: 38092727 Free PMC article.
Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: A multicentric retrospective study.
Gigante E, Bouattour M, Bedoya JU, Regnault H, Ziol M, Assenat E, Paradis V, Calderaro J, Ganne-Carrié N, Bouhier-Leporrier K, Amaddeo G, Nault JC. Gigante E, et al. Among authors: regnault h. United European Gastroenterol J. 2024 May;12(4):429-439. doi: 10.1002/ueg2.12503. Epub 2023 Dec 7. United European Gastroenterol J. 2024. PMID: 38059651 Free PMC article.
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Llovet JM, et al. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. Lancet Oncol. 2023. PMID: 38039993 Clinical Trial.
45 results